Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer

Figure 3

ELISPOT assay after the fourth vaccination of case 5 in the second protocol. In the wells that were preincubated without survivin-2B peptide (A) or with an HIV peptide (C), spots were almost not visualized. On the other hand, in the wells that were preincubated with survivin-2B peptide (B), many spots were visualized. These findings demonstrate that CD8-positive T cells separated from the patients' PBMCs had a peptide-specific IFN-γ response.

Back to article page